BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Reports that NV-387 Shows Strong Activity Against Influenza A

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the ultra-broad antiviral activity spectrum of NV-387 includes influenza A viruses, possibly including bird flu H5N1 virus as well. According to the announcement, the company performed a lethal animal model of lung infection by influenza A/H3N2 virus that indicated NV-387 showed superior antiviral effects compared to three approved anti-influenza drugs: Oseltamivir (Tamiflu[R], Roche), Peramivir (Rapivab[R], Biocryst), and Baloxivir (Xofluza[R], Shionogi, Roche).

“We are pleasantly surprised by this extremely broad and strong antiviral activity of NV-387,” said NanoViricides president and executive chair Anil R. Diwan, PhD, in the press release. “We are close to having a single drug NV-387 for the treatment of all of the tripledemic respiratory viruses — coronaviruses, RSV and influenza A — which would be a revolutionary achievement.”

To view the full press release, visit https://ibn.fm/R0bW9

About NanoViricides Inc.

NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides’ lead drug candidate is NV-CoV-2 for the treatment of RSV, COVID-19, Long COVID and other respiratory viral infections. The company’s other advanced candidate is NV-HHV-1 for the treatment of shingles (previously referred to as NV-HHV-101). The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. NanoViricides is currently focused on advancing NV-CoV-2 into phase 1/2 human clinical trials. To learn more about the company, visit www.NanoViricides.com.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN